Background: Adenocarcinoma of colon and rectum are one of the most common cancers worldwide, responsible for over 1,300,000 people diagnosed. Also, they are responsible for metastasis, which leads to death in less than 5 years.
Methods: In this study, we developed, characterized, and pre-clinically tested a new nano-radiopharmaceutical for early and differential detection of adenocarcinoma of colon and rectum.
Results and Conclusion: Results demonstrated the specificity of the developed nanosystem and the ability to reach the tumor with very specific targeting. Also, the imaging data support the use of this nano-agent as a nanoimaging- guided-radiopharmaceutical.
[http://dx.doi.org/10.1111/j.1440-1681.1998.tb02339.x] [PMID: 9807659]
[http://dx.doi.org/10.1080/21691401.2018.1443941] [PMID: 29482360]
[http://dx.doi.org/10.1016/j.jpba.2018.02.017] [PMID: 29471223]
[http://dx.doi.org/10.1289/ehp.9685] [PMID: 17520060]
[http://dx.doi.org/10.1002/1097-0142(197401)33:1<103:AID-CNCR2820330116>3.0.CO;2-7] [PMID: 4810083]